MedTrace Logo

Sorafenib Plus Capecitabine Efficacy Assessment in Patients With Advanced Pre-treated Colorectal Cancer

NCT01290926 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2016-02-24

No results posted yet for this study

Summary

Prospective non-randomized phase II study assessing the activity of the Capecitabine-Sorafenib combination by estimating overall survival of the study population at a fixed time point (6 months) and, as an exploratory analysis the overall survival of metabolic responders versus non-responders.

Conditions

Interventions

DRUG

chemotherapy

sorafenib 600mg/day capecitabine 1250 mg/m²/day

Sponsors & Collaborators

  • Erasme University Hospital

    collaborator OTHER

  • INDC Entité Jolimontoise

    collaborator UNKNOWN

  • Centre Hospitalier Chretien

    collaborator OTHER

  • Universiteit Antwerpen

    collaborator OTHER

  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    collaborator OTHER

  • Hospital Ambroise Paré Paris

    collaborator OTHER

  • Jules Bordet Institute

    lead OTHER

Principal Investigators

  • Alain Hendlisz, MD · Jules Bordet Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01290926 on ClinicalTrials.gov